Stanley R. Riddell

49.3k total citations · 22 hit papers
303 papers, 34.0k citations indexed

About

Stanley R. Riddell is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Stanley R. Riddell has authored 303 papers receiving a total of 34.0k indexed citations (citations by other indexed papers that have themselves been cited), including 186 papers in Oncology, 180 papers in Immunology and 65 papers in Epidemiology. Recurrent topics in Stanley R. Riddell's work include CAR-T cell therapy research (177 papers), Immune Cell Function and Interaction (110 papers) and Immunotherapy and Immune Responses (74 papers). Stanley R. Riddell is often cited by papers focused on CAR-T cell therapy research (177 papers), Immune Cell Function and Interaction (110 papers) and Immunotherapy and Immune Responses (74 papers). Stanley R. Riddell collaborates with scholars based in United States, South Africa and Germany. Stanley R. Riddell's co-authors include Philip D. Greenberg, Cameron J. Turtle, Michael C. Jensen, Edus H. Warren, David G. Maloney, Carolina Berger, Daniel Sommermeyer, Michael Hudecek, M. Jean Gilbert and Shivani Srivastava and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Stanley R. Riddell

296 papers receiving 33.4k citations

Hit Papers

Reconstitution of Cellula... 1992 2026 2003 2014 1995 1992 2017 2002 2001 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
    1995 1.5k citations Philip D. Greenberg, Stanley R. Riddell et al. profile →
  2. Restoration of Viral Immunity in Immunodeficient Humans by the Adoptive Transfer of T Cell Clones
    1992 1.0k citations Stanley R. Riddell, Philip D. Greenberg et al. Science profile →
  3. Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
    2017 948 citations Juliane Gust, Kevin A. Hay et al. Cancer Discovery profile →
  4. Adoptive T cell therapy using antigen-specific CD8+T cell clones for the treatment of patients with metastatic melanoma:In vivopersistence, migration, and antitumor effect of transferred T cells
    2002 941 citations Cassian Yee, Stanley R. Riddell et al. Proceedings of the National Academy of Sciences profile →
  5. Costimulation of CD8αβ T cells by NKG2D via engagement by MIC induced on virus-infected cells
    2001 803 citations Veronika Groh, Julie Randolph‐Habecker et al. profile →
  6. Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
    2017 787 citations Marie Bleakley, Catherine Lindgren et al. Blood profile →
  7. Comprehensive assessment of T-cell receptor β-chain diversity in αβ T cells
    2009 780 citations Cameron J. Turtle, Stanley R. Riddell et al. Blood profile →
  8. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy
    2017 775 citations Kevin A. Hay, Laïla‐Aïcha Hanafi et al. Blood profile →
  9. Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
    2016 741 citations Cameron J. Turtle, Laïla‐Aïcha Hanafi et al. profile →
  10. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates
    2008 654 citations Carolina Berger, Michael C. Jensen et al. profile →
  11. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
    2015 639 citations Daniel Sommermeyer, Michael Hudecek et al. profile →
  12. Therapeutic T cell engineering
    2017 628 citations Stanley R. Riddell et al. profile →
  13. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
    2008 573 citations Brian G. Till, Michael C. Jensen et al. Blood profile →
  14. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy
    2016 544 citations Michael C. Jensen, Stanley R. Riddell et al. Blood profile →
  15. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib
    2017 485 citations Cameron J. Turtle, Kevin A. Hay et al. profile →
  16. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells
    2011 472 citations Stephen J. Forman, Stanley R. Riddell et al. Blood profile →
  17. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
    2012 431 citations Brian G. Till, Michael C. Jensen et al. Blood profile →
  18. The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity
    2014 406 citations Michael Hudecek, Daniel Sommermeyer et al. Cancer Immunology Research profile →
  19. Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
    2017 391 citations Daniel Li, Kevin A. Hay et al. Blood profile →
  20. Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours
    2022 297 citations Stanley R. Riddell et al. profile →
  21. Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
    2020 227 citations Kevin A. Hay, Cecilia C.S. Yeung et al. Blood profile →
  22. Designed protein logic to target cells with precise combinations of surface antigens
    2020 144 citations Alexander I. Salter, Anusha Rajan et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stanley R. Riddell United States 98 20.5k 16.1k 7.8k 7.1k 6.5k 303 34.0k
Helen E. Heslop United States 84 21.3k 1.0× 10.8k 0.7× 5.6k 0.7× 7.7k 1.1× 5.4k 0.8× 426 28.1k
Cliona M. Rooney United States 93 24.6k 1.2× 12.6k 0.8× 6.3k 0.8× 8.8k 1.2× 6.7k 1.0× 388 31.4k
Malcolm K. Brenner United States 98 24.0k 1.2× 13.0k 0.8× 9.2k 1.2× 10.1k 1.4× 5.4k 0.8× 492 35.7k
Bruce L. Levine United States 76 22.8k 1.1× 13.9k 0.9× 9.2k 1.2× 7.8k 1.1× 1.3k 0.2× 255 32.7k
Adrian P. Gee United States 56 9.6k 0.5× 5.3k 0.3× 3.2k 0.4× 3.4k 0.5× 2.1k 0.3× 222 14.5k
Philip D. Greenberg United States 74 11.4k 0.6× 15.2k 0.9× 4.5k 0.6× 3.6k 0.5× 4.3k 0.7× 246 22.5k
Simon F. Lacey United States 50 11.9k 0.6× 4.5k 0.3× 3.9k 0.5× 3.6k 0.5× 1.1k 0.2× 157 15.0k
Lieping Chen United States 112 34.3k 1.7× 36.0k 2.2× 9.2k 1.2× 2.4k 0.3× 3.4k 0.5× 368 55.6k
Ton N. Schumacher Netherlands 83 17.9k 0.9× 22.7k 1.4× 9.7k 1.3× 2.4k 0.3× 2.2k 0.3× 311 34.3k
James L. Riley United States 67 9.7k 0.5× 12.3k 0.8× 4.1k 0.5× 2.5k 0.4× 1.4k 0.2× 149 18.8k

Countries citing papers authored by Stanley R. Riddell

Since Specialization
Citations

This map shows the geographic impact of Stanley R. Riddell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanley R. Riddell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanley R. Riddell more than expected).

Fields of papers citing papers by Stanley R. Riddell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanley R. Riddell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanley R. Riddell. The network helps show where Stanley R. Riddell may publish in the future.

Co-authorship network of co-authors of Stanley R. Riddell

This figure shows the co-authorship network connecting the top 25 collaborators of Stanley R. Riddell. A scholar is included among the top collaborators of Stanley R. Riddell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanley R. Riddell. Stanley R. Riddell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chu, Yaya, Gaurav Nayyar, Dean A. Lee, et al.. (2024). Efficiently targeting neuroblastoma with the combination of anti-ROR1 CAR NK cells and N-803 in vitro and in vivo in NB xenografts. SHILAP Revista de lepidopterología. 32(2). 200820–200820. 2 indexed citations
2.
Simon, Sylvain, et al.. (2021). Synthetic receptors for logic gated T cell recognition and function. Current Opinion in Immunology. 74. 9–17. 11 indexed citations
3.
Srivastava, Shivani, Jenny L. Smith, Amanda R. Leonti, et al.. (2021). Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia. Clinical Cancer Research. 27(20). 5718–5730. 17 indexed citations
4.
Balakrishnan, Ashwini, Anusha Rajan, Alexander I. Salter, et al.. (2019). Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors. Clinical Cancer Research. 25(24). 7506–7516. 48 indexed citations
5.
Veatch, Joshua, Julia Kargl, Matthew Fitzgibbon, et al.. (2019). Endogenous CD4+ T Cells Recognize Neoantigens in Lung Cancer Patients, Including Recurrent Oncogenic KRAS and ERBB2 ( Her2 ) Driver Mutations. Cancer Immunology Research. 7(6). 910–922. 70 indexed citations
6.
Gust, Juliane, Kevin A. Hay, Laïla‐Aïcha Hanafi, et al.. (2017). Endothelial Activation and Blood–Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells. Cancer Discovery. 7(12). 1404–1419. 948 indexed citations breakdown →
7.
Balakrishnan, Ashwini, Tracy Goodpaster, Julie Randolph‐Habecker, et al.. (2016). Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues. Clinical Cancer Research. 23(12). 3061–3071. 151 indexed citations
8.
Press, Oliver W., Philip Olsen, Sang Yun Lee, et al.. (2016). Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab. Cancer Immunology Research. 4(6). 509–519. 22 indexed citations
9.
Hudecek, Michael, Daniel Sommermeyer, Paula L. Kosasih, et al.. (2014). The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity. Cancer Immunology Research. 3(2). 125–135. 406 indexed citations breakdown →
10.
Hudecek, Michael, Maria Teresa Lupo Stanghellini, Paula L. Kosasih, et al.. (2013). Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells. Clinical Cancer Research. 19(12). 3153–3164. 424 indexed citations
11.
Till, Brian G., Michael C. Jensen, Jinjuan Wang, et al.. (2012). CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 119(17). 3940–3950. 431 indexed citations breakdown →
12.
Nishida, Tetsuya, Michael Hudecek, Ana Kostić, et al.. (2009). Development of Tumor-Reactive T Cells After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplant for Chronic Lymphocytic Leukemia. Clinical Cancer Research. 15(14). 4759–4768. 31 indexed citations
13.
Brown, Christine E., Renate Starr, Catalina Martínez, et al.. (2009). Recognition and Killing of Brain Tumor Stem-Like Initiating Cells by CD8+ Cytolytic T Cells. Cancer Research. 69(23). 8886–8893. 113 indexed citations
14.
Dai, Zhenpeng, Cameron J. Turtle, Garrett C. Booth, et al.. (2009). Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. The Journal of Experimental Medicine. 206(4). 793–805. 97 indexed citations
15.
Tykodi, Scott S., Nobuharu Fujii, Nathalie Vigneron, et al.. (2008). C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients. Clinical Cancer Research. 14(16). 5260–5269. 43 indexed citations
16.
Warren, Edus H., Nathalie Vigneron, Marc A. Gavin, et al.. (2006). An Antigen Produced by Splicing of Noncontiguous Peptides in the Reverse Order. Science. 313(5792). 1444–1447. 160 indexed citations
17.
Groh, Veronika, Daniel Cioca, Naomi Hunder, et al.. (2005). Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proceedings of the National Academy of Sciences. 102(18). 6461–6466. 74 indexed citations
18.
19.
Topp, Max S., Stanley R. Riddell, Yoshiki Akatsuka, et al.. (2003). Restoration of CD28 Expression in CD28− CD8 + Memory Effector T Cells Reconstitutes Antigen-induced IL-2 Production. The Journal of Experimental Medicine. 198(6). 947–955. 109 indexed citations
20.
Lewinsohn, Deborah A., Deborah A. Lewinsohn, David Lewinsohn, et al.. (2002). HIV-1 Vpr Does Not Inhibit CTL-Mediated Apoptosis of HIV-1 Infected Cells. Virology. 294(1). 13–21. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Helen E. Heslop Breakdown of academic impact, for papers by Cliona M. Rooney Breakdown of academic impact, for papers by Malcolm K. Brenner Breakdown of academic impact, for papers by Bruce L. Levine Breakdown of academic impact, for papers by Adrian P. Gee Breakdown of academic impact, for papers by Philip D. Greenberg Breakdown of academic impact, for papers by Simon F. Lacey Breakdown of academic impact, for papers by Lieping Chen Breakdown of academic impact, for papers by Ton N. Schumacher Breakdown of academic impact, for papers by James L. Riley
Rankless by CCL
2026